RxDoctor Payments Data

Jason Choi, MD

Cardiovascular Disease · Santa Maria, CANPI 1407083470

Payments from drug & device makers

$3,952in general payments, 2019–2025

Across 128 payments — averaging $30.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$1K
  • Boston Scientific$801
  • Globus Medical$509
  • Abbott$396
  • Amgen$239
  • Johnson & Johnson$221
  • plus $742 from 16 others

What the payments were for

  • Travel & lodging$1,04326%
  • Food & beverage$2,89473%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,952 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$588,485
Medicare patients
2,067
Services billed
4,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$319,519
XareltoRivaroxaban111$138,208
EntrestoSacubitril/Valsartan112$107,614
Repatha SureclickEvolocumab43$41,023
BrilintaTicagrelor39$30,276
JardianceEmpagliflozin29$27,269
Repatha SyringeEvolocumab15$13,964
Praluent PenAlirocumab20$12,509
NexletolBempedoic Acid17$9,816
Metoprolol Succinate375$5,349
Ezetimibe102$3,794
Prasugrel Hcl17$3,714
Atorvastatin Calcium319$2,619
Rosuvastatin Calcium200$2,617
Icosapent Ethyl11$2,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$319,519302 claims
Johnson & JohnsonXarelto$221$138,208111 claims
NovartisEntresto$84$107,614112 claims
AstraZenecaBrilinta$17$30,27639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →